- Home
- ACAD vs PATK Comparison
ACAD vs PATK Comparison
Compare ACAD & PATK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PATK
- Stock Information
- Founded
- ACAD 1993
- PATK 1959
- Country
- ACAD United States
- PATK United States
- Employees
- ACAD N/A
- PATK N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PATK Auto Parts:O.E.M.
- Sector
- ACAD Health Care
- PATK Consumer Discretionary
- Exchange
- ACAD Nasdaq
- PATK Nasdaq
- Market Cap
- ACAD 4.0B
- PATK 3.8B
- IPO Year
- ACAD 2004
- PATK N/A
- Fundamental
- Price
- ACAD $25.99
- PATK $111.62
- Analyst Decision
- ACAD Buy
- PATK Buy
- Analyst Count
- ACAD 20
- PATK 10
- Target Price
- ACAD $28.63
- PATK $104.50
- AVG Volume (30 Days)
- ACAD 2.0M
- PATK 331.4K
- Earning Date
- ACAD 08-06-2025
- PATK 10-30-2025
- Dividend Yield
- ACAD N/A
- PATK 1.43%
- EPS Growth
- ACAD 615.00
- PATK N/A
- EPS
- ACAD 1.33
- PATK 3.69
- Revenue
- ACAD $1,018,885,000.00
- PATK $3,816,541,000.00
- Revenue This Year
- ACAD $14.01
- PATK $3.72
- Revenue Next Year
- ACAD $11.72
- PATK $5.55
- P/E Ratio
- ACAD $19.61
- PATK $30.29
- Revenue Growth
- ACAD 14.41
- PATK 6.09
- 52 Week Low
- ACAD $13.40
- PATK $72.99
- 52 Week High
- ACAD $26.65
- PATK $116.78
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- PATK 63.60
- Support Level
- ACAD $25.14
- PATK $110.50
- Resistance Level
- ACAD $26.65
- PATK $116.78
- Average True Range (ATR)
- ACAD 0.67
- PATK 3.60
- MACD
- ACAD 0.04
- PATK 0.08
- Stochastic Oscillator
- ACAD 70.27
- PATK 79.48
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PATK Patrick Industries Inc.
Patrick Industries Inc makes and sells building products and materials for recreational vehicles and manufactured housing. The company is organized into two segments based on product type: manufacturing and distribution. The manufacturing segment, which generates the majority of revenue, sells laminated and vinyl products that include furniture, shelving, cabinets, bath fixtures, and countertops. The distribution segment sells prefinished wall and ceiling panels, as well as electrical and plumbing products for the RV and manufactured housing industries. One of the firm's RV customers makes up a portion of revenue.